Daily FNArena News - Small Caps

All | Australia | Book Reviews | Commodities | ESG Focus | FYI | International | Small Caps | Technicals | Treasure Chest

Latest Stories

Tim Boreham reports cancer treatment biotech Chimeric has struggled, but may yet have a sting in its tail

May 26 2023

Brokers remain enthusiastic on the outlook for Life360 following first quarter results

May 23 2023

Strong demand projections for nickel have put ASX-listed Nickel Industries on investors’ radar, but the company’s outlook is not risk-free

May 18 2023

Brokers review first quarter results and pending regulatory approvals for Avita Medical

May 17 2023

Previous Stories

Judo Capital Offers Differentation

May 11 2023

Brokers continue to rate Judo Capital highly despite looming macroeconomic headwinds

Dr Boreham’s Crucible: Impedimed

May 08 2023

Tim Boreham reports a change in CEO has given cancer monitoring biotech Impedimed a new lease of life

Artificial Intelligence On The ASX

May 02 2023

The ASX-listed AI sector can be split between tech providers developing AI tools and non-tech companies using AI to improve their existing business

Dr Boreham’s Crucible: Volpara Health Technologies

Apr 26 2023

Volpara Health Technologies is revolutionising breast cancer detection. Tim Boreham investigates

Dr Boreham’s Crucible: Radiopharm Theronostics

Apr 13 2023

Cancer detection biotech Radiopharm Theronostics is planning to list on the Nasdaq, and not without good reason, Tim Boreham explains

Cybersecurity On The ASX

Apr 11 2023

It’s impossible to picture a future without cybersecurity. The ASX hosts a smorgasboard in potential exposures

Dr Boreham’s Crucible: Avita Medical

Mar 29 2023

Tim Boreham highlights the global addressable market opportunity for Avita Medical’s skin graft technology, made famous by the Bali bombings

Helloworld Turnaround Now Includes Europe

Mar 28 2023

Tapping into the Scandinavian market, Helloworld has acquired an interest in Norway-based Australiareiser, bringing its ResWorld platform to Europe

Telix Pharmaceuticals’ Pipeline Full Of Promise

Mar 21 2023

Following FY22 results for Telix Pharmaceuticals brokers remain Buy-rated in light of an extensive pipeline of new products under development

FDA Approval Puts Rocket Under Neuren Shares

Mar 16 2023

Amidst a sea of red, the Neuren share price has skyrocketed in recent days following a world first approval for the biotech’s treatment of Rett syndrome

Analyse The Market From A Different Angle